Cognitive Impairment in Major Depressive Disorder Clinical Relevance, Biological Substrates, and Treatment Opportunities
Book contents
- Cognitive Impairment in Major Depressive DisorderClinical Relevance, Biological Substrates, and Treatment Opportunities
- Cognitive Impairment in Major Depressive Disorder
- Copyright page
- Contents
- Figures
- Tables
- Contributors
- Preface
- Abbreviations
- Part I Clinical relevance of cognitive dysfunction in major depressive disorder
- Part II Underlying biological substrates associated with cognitive dysfunction in major depressive disorder
- Part III Evaluating cognitive dysfunction in major depressive disorder
- 16 Measuring the mind: detecting cognitive deficits and measuring cognitive change in patients with depression
- 17 Subjective measures of cognitive dysfunction in major depressive disorder
- Part IV Treatment opportunities for ameliorating cognitive dysfunction in major depressive disorder
- Index
- References
16 - Measuring the mind: detecting cognitive deficits and measuring cognitive change in patients with depression
from Part III - Evaluating cognitive dysfunction in major depressive disorder
Published online by Cambridge University Press: 05 March 2016
Book contents
- Cognitive Impairment in Major Depressive DisorderClinical Relevance, Biological Substrates, and Treatment Opportunities
- Cognitive Impairment in Major Depressive Disorder
- Copyright page
- Contents
- Figures
- Tables
- Contributors
- Preface
- Abbreviations
- Part I Clinical relevance of cognitive dysfunction in major depressive disorder
- Part II Underlying biological substrates associated with cognitive dysfunction in major depressive disorder
- Part III Evaluating cognitive dysfunction in major depressive disorder
- 16 Measuring the mind: detecting cognitive deficits and measuring cognitive change in patients with depression
- 17 Subjective measures of cognitive dysfunction in major depressive disorder
- Part IV Treatment opportunities for ameliorating cognitive dysfunction in major depressive disorder
- Index
- References
- Type
- Chapter
- Information
- Cognitive Impairment in Major Depressive DisorderClinical Relevance, Biological Substrates, and Treatment Opportunities, pp. 229 - 241Publisher: Cambridge University PressPrint publication year: 2016
References
Conradi, H. J., Ormel, J., & de Jonge, P. (2011). Presence of individual (residual) symptoms during depressive episodes and periods of remission: A 3-year prospective study. Psychological Medicine, 41(6): 1165–1174.CrossRefGoogle ScholarPubMed
Ferris, S. H., Lucca, U., Mohs, R., Dubois, B., Wesnes, K., Erzigkeit, H., … Bodick, N. (1997). Objective psychometric tests in clinical trials of dementia drugs: Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Disease and Associated Disorders, 11(Suppl. 3): 34–38.Google Scholar
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975). “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12: 189–198.CrossRefGoogle ScholarPubMed
Grober, E. and Sliwinski, M. (1991). Development and validation of a model for estimating premorbid verbal intelligence in the elderly. Journal of Clinical and Experimental Neuropsychology, 13(6): 933–949.CrossRefGoogle Scholar
Harrison, J., Buxton, P., Husain, M., & Wise, R. (2000). Short test of semantic and phonological fluency: Normal performance, validity and test-retest reliability. British Journal of Clinical Psychology, 39(2): 181–191.Google Scholar
Harrison, J., Lophaven, S., & Olsen, C. K. (2014). Which cognitive domains are improved by treatment with vortioxetine? Poster NR6-105 at the American Psychiatric Association Meeting, New York.Google Scholar
Harrison, J. and Maruff, P. (2008). Measuring the mind: Assessing cognitive change in clinical drug trials. Expert Reviews in Clinical Pharmacology, 1(4): 471–473.Google Scholar
Harrison, J., Minassian, S. L., Jenkins, L., Black, R. S., Koller, M., & Grundman, M. (2007). A neuropsychological test battery for use in Alzheimer disease clinical trials. Archives of Neurology, 64(9): 1323–1329.Google Scholar
Henderson, L., Harrison, J., & Kennard, C. (2001). Selectively impaired reaction time in Parkinson’s disease: Persistent absence of simple reaction advantage in a patient with frontal complications. Neurocase, 7(4): 319–330.Google Scholar
Hilt, D., Gawryl, M., & Koenig, G. (2009). ECP-6124: Safety, tolerability and cognitive effects of a novel A7 nicotinic receptor agonist in Alzheimer’s disease patients on stable donepezil or rivastigmine therapy. Alzheimer’s & Dementia: Journal of the Alzheimer’s Association, 5(4): e32. doi: http://dx.doi.org/10.1016/J.jalz.2009.07.147.CrossRefGoogle Scholar
Hufford, M. R., Davis, V. G., Hilt, D., Dgetluck, N., Geffen, Y., Loebel, A., … Keefe, R. S. E. (2014). Circadian rhythms in cognitive functioning among patients with schizophrenia: Impact on signal detection in clinical trials of pro-cognitive therapies. Schizophrenia Research. doi: http://dx.doi.org/10.1016/j.schres.2014.07.018.Google Scholar
Katona, C., Hansen, T., & Olsen, C. K. (2012). A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. International Clinical Psychopharmacology, 27(4): 215–223.Google Scholar
Lam, R. W., Saragoussi, D., Danchenko, N., Rive, B., Lamy, F. X., & Brevig, T. (2013). Psychometric Validation of Perceived Deficits Questionnaire – Depression (PDQ–D) in patients with major depressive disorder (MDD). Value in Health, 16(7): A330.CrossRefGoogle Scholar
Lee, R. S. C., Hermens, D. F., Porter, M. A., & Redoblado-Hodge, M. A. (2012). A meta-analysis of cognitive deficits in first-episode major depressive disorder. Journal of Affective Disorders, 140(2): 113–124.Google Scholar
Lovera, J., Bagert, B., Smoot, K. H., Wild, K., Frank, R., Bogardus, K., … Bourdette, D. N. (2006). Correlations of Perceived Deficits Questionnaire of Multiple Sclerosis Quality of Life Inventory with Beck Depression Inventory and neuropsychological tests. Journal of Rehabilitation Research and Development, 43(1): 73–82.CrossRefGoogle ScholarPubMed
McIntyre, R. S., Lophaven, S., & Olsen, C. K. (2014). A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. International Journal of Neuropsychopharmacology, 17(10): 1557–1567.Google Scholar
Nasreddine, Z. S., Phillips, N. A., Bédirian, V., Charbonneau, S., Whitehead, V., Collin, I., … Chertkow, H. (2005). The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment. Journal of the American Geriatrics Society, 53(4): 695–699.CrossRefGoogle Scholar
Nelson, H. E. (1982). The National Adult Reading Test (NART): Test Manual. Windsor: NFER-Nelson.Google Scholar
Nuechterlein, K. H., Green, M. F., Kern, R. S., Baade, L. E., Barch, D. M., Cohen, J. D., … Marder, S. R. (2008). The MATRICS Consensus Cognitive Battery, part 1: Test selection, reliability, and validity. American Journal of Psychiatry, 165(2): 203–213.Google Scholar
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999). Mild cognitive impairment: Clinical characterization and outcome. Archives of Neurology, 56(3): 303–308.Google Scholar
Rock, P. L., Roiser, J. P., Riedel, W. J., & Blackwell, A. D. (2014). Cognitive impairment in depression: A systematic review and meta-analysis. Psychological Medicine, 44: 2029–2040.CrossRefGoogle ScholarPubMed
Rosen, W. G., Mohs, R. C., & Davis, K. L. (1984). A new rating scale for Alzheimer’s disease. American Journal of Psychiatry, 141(11): 1356–1364.Google Scholar
Taylor, B. N. & Kuyatt, C. E. (1994). NIST Technical Note 1297 Guidelines for Evaluating and Expressing the Uncertainty of NIST Measurement Results. Physics Laboratory National Institute of Standards and Technology, Gaithersburg, MD 20899–0001.Google Scholar
- 8
- Cited by